Retinal ultrastructural, electrophysiological and microvascular morphological outcomes in diabetic macular edema treated with intravitreal bevacizumab
Закрыть
Articolul precedent
Articolul urmator
334 0
SM ISO690:2012
GULYESIL, Furkan Fatih, INAN, Sibel, SABANER, Mehmet Cem, ALIZADE, Anar, GOBEKA, Hamidu Hamisi. Retinal ultrastructural, electrophysiological and microvascular morphological outcomes in diabetic macular edema treated with intravitreal bevacizumab. In: Black Sea Ophthalmological Society Congress, Ed. 19, 24-26 septembrie 2021, Chisinau. Chişinău: CEP UPS „I.Creangă”, 2021, Ediția 19, p. 58.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Black Sea Ophthalmological Society Congress
Ediția 19, 2021
Congresul "Black Sea Ophthalmological Society Congress, "
19, Chisinau, Moldova, 24-26 septembrie 2021

Retinal ultrastructural, electrophysiological and microvascular morphological outcomes in diabetic macular edema treated with intravitreal bevacizumab


Pag. 58-58

Gulyesil Furkan Fatih1, Inan Sibel1, Sabaner Mehmet Cem1, Alizade Anar1, Gobeka Hamidu Hamisi2
 
1 Afyonkarahisar Health Sciences University,
2 Ağrı İbrahim Çeçen University
 
 
Disponibil în IBN: 10 mai 2022


Rezumat

Purpose: To investigate retinal ultrastructural, electrophysiological, and microvascular morphological changes, as well as correlations between these changes and visual outcome in naïve diabetic macular edema (DME) patients after intravitreal bevacizumab therapy Design: A prospective interventional study Methods: A total of 31 DME patients’ eyes had monthly intravitreal bevacizumab injections for three consecutive months. Best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were measured, and fundus fluorescein angiography, optical coherence tomography (OCT), microperimetry (MP), as well as optical coherence tomography angiography (OCTA) were performed before and after therapy. Patients were then grouped based on BCVA improvement after three consecutive intravitreal injections: group 1- >10 letters, group 2- ≤5 letters, and group 3- between 6 and 10 letters. Results: Mean BCVA increased significantly after therapy, rising from 34.2 to 39.9 letters (p<0.001). The central macular thickness (CMT) decreased significantly from baseline 335.1 μm to 276.4 μm (p<0.001). Fixation stability, mean retinal sensitivity, and mean local deficit all improved significantly after therapy (p<0.001 for all). There was no statistically significant change in IOP before and after therapy (p=0.665). While OCTA parameters did not change significantly, patients with lower foveal avascular zone area, higher FD-300 and deep plexus vascular density showed better improvements in mean BCVA, retinal sensitivity, and local defect. Also, there were no significant intergroup differences in gender, age, baseline BCVA, HbA1c, IOP, phakic/pseudophakic lens ratio, presence of concomitant hypertension, and superficial capillary plexus vascular density. Conclusions: Intravitreal bevacizumab therapy was associated with significantly improved BCVA, retinal ultrastructural integrity, and electrophysiological patterns in naive DME patients. Improvements in retinal electrophysiology correlated with ultrastructural improvements, which could be predicted using OCTA.